Correlation between pathologic complete response, event-free survival/disease-free survival and overall survival in neoadjuvant and/or adjuvant HR+/HER2-breast cancer

20232 citationsReviewgold Open Access

Authors

Anagha Gogate · Bristol-Myers Squibb (United States)

Sandip Ranjan

Amit Kumar

Hitesh Bhandari

Eros Papademetriou · Amethyst Technologies (United States)

Inkyu Kim · Bristol-Myers Squibb (United States)

Ravi Potluri · Amethyst Technologies (United States)

Abstract

EFS/DFS were moderately correlated with OS in this trial-level analysis. They may be considered as valid surrogates for OS in HR+/HER2- breast cancer.

Topics & Keywords

Breast Cancer Treatment Studies Genetic factors in colorectal cancer Cancer Genomics and Diagnostics

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: Frontiers in Oncology

Volume 13, pp. 1119102-1119102

DOI: 10.3389/fonc.2023.1119102

Field-Weighted Citation Impact: 0.49